We are informed by European Patent Office that on expiry of the opposition period no notice of opposition has been filed against the NBHL’s European patent for anti-CCR7 antibodies granted in 2019. 

Title of the invention: Anti-human CCR7 antibodies, hybridoma, medical composition, and antibody-immobilized carrier

Patent number: EP 2 623 592

Application number: 11829086.5

Proprietor: NB Health Laboratory Co. Ltd.

 CCR7 is a GPCR involved in the pathogenesis of fibrosis and cancer. We will continue to proceed with the development of therapeutic anti-CCR7 antibodies.